Epidemiological Impact of a Genital Herpes Type 2 Vaccine for Young Females

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lou, Yijun ^a,b   Qesmi, Redouane ^a,c   Wang, Qian ^a   Steben, Marc ^d   Wu, Jianhong ^a   Heffernan, Jane M ^a  

^a YORK UNIVERSITY   (Canada)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GENITAL HERPES; HEALTH PROGRAM; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOUTH INFECTION; OUTCOME ASSESSMENT; PREVALENCE; PROCESS DEVELOPMENT; SAFE SEX; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SEXUAL BEHAVIOR; SEXUAL EDUCATION; SEXUAL MATURITY; VACCINATION; VIRUS INHIBITION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; VIRAL VACCINES; YOUNG ADULT;

EID: 84867435738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046027     Document Type: Article

References (50)

1. Steben M, Money D, Wong T, Gruslin A, Yudin M, et al. (2008) Genital herpes: gynaecological aspects. J Obstet Gynaecol Can 30: 347-361.
2. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, et al. (2009) Frequent Release of Low Amounts of Herpes Simplex Virus From Neurons: Results of a Mathematical Model. Sci Transl Med 1: 7ra16.
3. Mertz GJ, Rosenthal SL, Stanberry LR, (2003) Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes? Sex Transm Dis 30: 801-802.
4. World Health Organization. (2001) Herpes simplex virus type 2: programmatic and research priorities in developing countries. Report of a WHO/UNAIDS/LSHTM workshop, London, 14-16 February 2001.
5. Armstrong GL, Schillinger J, Markowitz L, Nahmias AJ, Johnson RE, et al. (2001) Incidence of herpes simplex virus type 2 infection in the united states. Am J Epidemiol 153: 912-920.
6. Centers for Disease Control and Prevention. Available: www.cdc.gov/std/herpes/stdfact-herpes.htm. Accessed 2012 Mar 1.
7. Vezina C, Steben M, (2001) Genital Herpes: Psychosexual Impacts and Counselling. Can J Cont Med Ed 13: 125-137.
8. Freeman E, Weiss H, Glynn J, Cross P, Whitworth JA, et al. (2006) Herpes simplex virus type 2 increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20: 73-83.
9. Wald A, Link K, (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185: 45-52.
10. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, et al. (1991) Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. New England Journal of Medicine 324: 1247-1252.
11. GlaxoSmithKline. Gsk data on file rm2000/00317/00.
12. Wald A, Andria, Langenberg, Krantz E, Douglas JM, et al. (2005) The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 143: 707-713.
13. Brugha R, Keersmaekers K, Renton A, Meheus A, (1997) Genital herpes infection: a review. Int J Epidemiol 26: 698-709.
14. National Institute of Allergy and Infectious Diseases (NIAID). Accessed 2012 Mar 1.
15. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, et al. (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771.
16. FOCUS (2008) Herpes Vaccine Developed at HMS Licensed for Preclinical Trials. Available: http://archives.focus.hms.harvard.edu/2008/030708/licensing.shtml. Accessed 2012 Mar 1.
17. Alsallaq RA, Schiffer JT, Longini IM, Wald A, Corey L, et al. (2010) Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sexually transmitted diseases 37: 290-297.
18. Foss AM, Vickerman PT, Chalabi Z, Mayaud P, Alary M, et al. (2009) Dynamic modeling of herpes simplex virus type-2 (HSV-2) transmission: Issues in structural uncertainty. Bull Math Biol 71: 720-749.
19. Garnett GP, Dubin G, Slaoui M, Darcis T, (2004) The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 80: 24-29.
20. Podder CN, Gumel AB, (2010) Qualitative dynamics of a vaccination model for HSV-2. IMA J Appl Math 75: 75-107.
21. Schwartz EJ, Blower S, (2005) Predicting the potential individual and population-level effects of imperfect herpes simplex virus type 2 vaccines. J Infect Dis 191: 1734-1746.
22. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, et al. (1997) Herpes simplex virus type 2 in the united states, 1976 to 1994. New England Journal of Medicine 337: 1105-1111.
23. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, et al. (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. J Am Med Assoc 296: 964-973.
24. Nahmias AJ, Lee FK, Beckman-Nahmias S, (1990) Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 69 pp. 19-36.
25. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L, (1992) Risk factors for the sexual transmission of genital herpes. Ann Intern Med 116: 197-202.
26. Kebede Y, Dorigo-Zetsma W, Mengistu Y, Mekonnen Y, Schaap A, et al. (2004) Transmission of herpes simplex virus Type 2 among factory workers in Ethiopia. J Infect Dis 190: 365-372.
27. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein- d-adjuvant vaccine to prevent genital herpes. New England Journal of Medicine 347: 1652-1661.
28. American Social Health Association. Available: www.ashastd.org/std-sti/Herpes/learn-about-herpes. Accessed 2012 Mar 1.
29. Lowhagen GB, Tunback P, Bergstrom T, (2002) Proportion of herpes simplex virus (HSV) type 1 and type 2 among genital and extragenital HSV isolates. Acta Derm Venereol 82: 118-120.
30. Public Health Agency of Canada: Canadian Immunization Committee (2007) Recommendations on a human papillomavirus immunization program. Available: www.phac-aspc.gc.ca/publicat/2008/papillomavirus-papillome/papillomavirus-papillome-11-eng.php. Accessed 2012 Mar 1.
31. Blower SM, Porco TC, Darby G, (1998) Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 4: 673-678.
32. Roberts MG, Heesterbeek JAP (2004) Mathematical models in epidemiology. In: Filar JA, Krawczyk JB, eds. Mathematical Models, in Encyclopedia of Life Support Systems (EOLSS). Oxford, UK: Developed under the Auspices of the UNESCO, Eolss Publishers.
33. Webb PM, Zimet GD, Mays R, Fortenberry JD, (1999) HIV immunization: acceptability and anticipated effects on sexual behavior among adolescents. J Adolescent Health 25: 320-322.
34. Straus S, Savarese B, Krause P, Kost R, Meier J, et al. (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein d of herpes simplex virus type 2 for immunotherapy of genital herpes. The Lancet 343: 1460-1463.
35. Canada S (2001) Cansim table 102-0511 and catalogue no. 84-537-xie. Available: www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health72a-eng.htm. Accessed 2012 Mar 1.
36. Patrick DM, Dawar M, Cook DA, Krajden M, Ng HC, et al. (2001) Antenatal seroprevalence of herpes simplex virus type 2 (HSV-2) in Canadian Women: HSV-2 Prevalence increases throughout the reproductive years. Sex Transm Dis 28: 424-428.
37. Singh A, Wong T, Howlett R, (2008) Human papillomavirus vaccines: Why the time is right to implement immunization and surveillance programs in Canada. Can J Infect Dis Med Microbiol 9: 294-296.
38. Warren CW, Santelli JS, Everett SA, Kann L, Collins JL, et al. (1998) Sexual behavior among U.S. high school students, 1990-1995. Fam Plann Perspect 30: 170-200.
39. Blower S, Wald A, Gershengorn H, Wang F, Corey L, (2004) Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J Infect Dis Soci Am 190: 1610-1617.
40. Lepkowski JM, Mosher WD, Davis KE, Groves RM, Van Hoewyk J, (2010) The 2006-2010 national survey of family growth: Sample design and analysis of a continuous survey. 2: 1-36.
41. Statistics Canada (2011) Canadian Community Health Survey-Annual Component (CCHS).
42. Llamazares M, Smith RJ, (2008) Evaluating human papillomavirus vaccination programs in Canada: should primary healthcare pay for adult vaccination? BMC Public Health 8: 114.
43. Schillinger JA, McKinney CM, Garg R, Gwynn RC, White K, et al. (2008) Seroprevalence of herpes simplex virus type 2 and characterisitics associated with undiagnosed infection: New York city, 2004. Sex Transm Dis 35: 599-606.
44. Heffernan JM, Smith RJ, Wahl LM, (2005) Perspectives on the basic reproductive ratio. J R Soc Interface 2: 281-293.
45. Heesterbeek JAP, Dietz K, (1996) The concept of R0 in epidemic theory. Stat Neerl 50: 89-110.
46. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, et al. (2004) Once-daily valacyclovir to reduce the risk of transmission of genital herpes. New England Journal of Medicine 350: 11-20.
47. Blower SM, Dowlatabadi H, (1994) Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: An HIV Model, as an Example. International Statistical Review/Revue Internationale de Statistique 62: 229-243.
48. Marino S, Hogue IB, Ray CJ, Kirschner DE, (2008) A methodology for performing global uncer-tainty and sensitivity analysis in systems biology. J Theor Biol 254: 178-196.
49. Mark KE, Wald A, Magaret AS, Selke S, Olin L, et al. (2008) Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 198: 1141-1149.
50. World Health Organization. Initiative for vaccine research (ivr). Sexually transmitted diseases. Available: www.who.int/vaccine_research/diseases/soa_std/en/index3.html. Accessed 2012 Mar 1.